Nanotechnology Now

Our NanoNews Digest Sponsors





Heifer International

Wikipedia Affiliate Button


android tablet pc

Home > Press > Luna Innovations Reports Fourth Quarter and Full Year 2006 Financial Results

Abstract:
Company Achieves 51% Revenue Growth for the Fourth Quarter 2006; Gross Profits Improve to 30% from 17% in Fourth Quarter 2005; Company Provides Guidance for Fiscal Year 2007.

Luna Innovations Reports Fourth Quarter and Full Year 2006 Financial Results

ROANOKE, VA | Posted on March 5th, 2007

Luna Innovations Incorporated (Nasdaq: LUNA) today announced its financial results for the
fourth quarter and full year ended December 31, 2006.

Kent Murphy, Chairman and Chief Executive Officer, commented, "The top-
line growth and gross margin expansion we experienced in the fourth quarter
and full year of 2006 were largely propelled by the growth of higher margin
revenues from the sale of products. We are beginning to experience the
benefits and validation of the Luna business model. Product and license
sales accounted for 28% of our revenue, compared to 20% in fourth quarter
of 2005, and 19% in the third quarter of 2006, and as we experienced that
growth, our overall gross profit margin grew from 17% in the fourth quarter
of 2005 to 30% in the fourth quarter of 2006."

Revenues for the fourth quarter of 2006 increased 51% to $8.0 million
from $5.3 million for the same quarter of 2005, reflecting growth in
technology development (contract research) revenues of approximately $1.5
million and growth in product and license revenues of approximately $1.2
million. Gross profit increased to $2.4 million, or 30% of revenues, in the
fourth quarter of 2006, from $0.9 million, or 17% of revenues, in the
fourth quarter of 2005. Operating expenses were $5.3 million in the fourth
quarter of 2006, compared to $4.1 million in the third quarter of 2006 and
$3.1 million in the fourth quarter of 2005. The increase in year over year
operating expense reflects the company's strategy, begun in late 2005, to
increase its product portfolio and product sales, which included the
acquisition of Luna Technologies in September 2005. Operating expenses in
the fourth quarter of 2006 were also higher than the prior quarter because
increased product sales resulted in higher commissions for the company's
internal sales force and third party re- sellers, the company expanded its
leased facilities to accommodate growth, and additional resources were
devoted to preparation of bids and proposals for new technology development
opportunities. During the quarter, the company also incurred approximately
$0.2 million in expenses related to engineering and other start-up costs
associated with recently acquired product lines and $0.3 million in legal
and related costs associated with the successful resolution of a
contractual dispute. The company incurred a loss from operations of $2.9
million in the fourth quarter of 2006, versus a loss from operations of
$2.1 million for the prior year's comparable quarter.

The net loss applicable to common stockholders for the fourth quarter
of 2006 was $2.7 million, or $0.27 per share on a diluted basis, compared
to a net loss applicable to common stockholders of $1.7 million or $0.33
per share, for the fourth quarter of 2005.

Murphy added, "Our Luna Technologies subsidiary saw record fourth
quarter revenue of $1.8 million and record bookings of $2.0 million. We
signed 12 new customers in the fourth quarter, including many top tier
companies, and we signed eight contracts with repeat customers, which
resulted in a 70% growth rate within Luna Technologies compared to the
fourth quarter of 2005. We also acquired the rights to manufacture and sell
a line of swept tunable lasers. We expect the technology will allow us to
compete more effectively in our existing fiber optic test and measurement
markets and open up new markets in industrial and medical sensing. On the
healthcare products side, we continued to ship units of our Emboli
Detection and Classification (EDAC(TM)) product to research institutions
and are currently working through a third party to obtain FDA clearance for
clinical use."

For the year ended December 31, 2006, total revenues were $23.5
million, compared to $16.5 million 2005. Technology development revenue for
2006 increased $3.4 million, or 22%, over 2005. Product and license revenue
was $4.8 million in 2006. Gross profit increased to $7.1 million, or 30% of
revenues, for 2006, from $3.5 million, or 21% of revenues, in 2005.
Operating expenses were $17.1 million in 2006, compared to $6.0 million in
2005. The increase in year over year operating expenses reflects the
company's strategy to increase its product portfolio and product sales.
Operating expenses in 2006 also include share-based compensation expense as
well as administrative costs associated with the company's growing employee
base and its transformation to a public company. The company incurred a
loss from operations of $10.0 million in 2006, versus a loss from
operations of $2.5 million for the prior year.

The net loss applicable to common stockholders for 2006 was $9.4
million, or $1.14 per share on a diluted basis, compared to a net loss
applicable to common stockholders of $2.0 million, or $0.53 per share, for
the previous year.
Fourth Quarter Business Highlights

Technology Development

-- Booked more than $4 million in new technology development contracts
in the fourth quarter 2006, for a total of more than $22 million in
new technology development contracts during the full year 2006.

Healthcare Products

-- Submitted 510(k) documentation for the company's EDAC product to an
FDA-accredited third-party reviewer. The purpose of this review is to
shorten the overall timeframe required to receive FDA clearance and
begin marketing the product for clinical use.

-- Completed preliminary animal testing for the non-invasive diagnosis
of compartment syndrome using the company's EN-TACT(TM) (Emergency
Noninvasive Tissue and Compartment Testing) product.

-- Validated improved MRI image contrast performance using
Trimetasphere(TM) nanomaterials. Improved image contrast is expected,
together with improved safety, to be one of the primary potential
advantages of the company's MRI contrast agent product candidates
over current commercially available products.

Instrumentation, Test and Measurement Products

-- Introduced a new distributed sensing technique that is expected to
significantly reduce the expense associated with the deployment and
maintenance of fiber optics.

-- Acquired the rights to manufacture and sell an existing line of swept
tunable lasers. The company anticipates the technology will allow it
to compete more effectively in the fiber optic test and measurement
markets by providing customers with fast, flexible and cost-effective
test and measurement products. This laser technology also allows the
company to aggressively pursue business opportunities in new markets
such as industrial and medical sensing.

-- Booked over $2 million in product orders during the quarter.


Fourth Quarter Financial Highlights

-- Revenues for the fourth quarter of 2006 increased 51% compared to the
fourth quarter of 2005 and 33% compared to the third quarter of 2006.

-- Product revenues represented over 27% of total revenues in the fourth
quarter of 2006, versus 20% in the fourth quarter of 2005, and 19% in
the third quarter of 2006. Product revenues grew to approximately
$2.2 million in the fourth quarter of 2006, versus $1.2 million in
the third quarter of 2006.

-- Gross profit for the fourth quarter of 2006 increased to $2.4
million, or 30% of revenues, from $0.9 million, or 17% of revenues,
for the corresponding period of 2005.

-- The company reported a loss per share for the fourth quarter of 2006
of $0.27 per share, on a diluted basis, compared to a loss per share
of $0.33 for the fourth quarter of 2005.

-- Cash and cash equivalents totaled $17.9 million at December 31, 2006,
compared to $12.5 million at December 31, 2005.

Outlook for Fiscal Year 2007

The company anticipates continued strong growth in both its product and
technology development divisions in 2007. For fiscal year 2007, the company
expects total revenue to be in the range of $30.0 million to $32.0 million,
consisting of product and license revenue of $7.0 to $8.0 million and
technology development revenue of $23.0 to $24.0 million. For the full year
2007, the company anticipates a net loss in the range of $9.0 to $9.5
million. For the first quarter of 2007, the company expects revenue of
approximately $6.9 million and a net loss of approximately $3.3 million.
The company plans to discuss its fiscal year 2007 guidance on its investor
conference call to be held later today.

Conference Call Information

As previously announced, Luna Innovations will conduct an investor
conference call at 5:00 p.m. (EST) today to discuss the company's fourth
quarter and full year 2006 financial results. The company will also discuss
expectations for 2007. The call can be accessed by dialing 1.800.638.5495
domestically or 1.617.614.3946 internationally prior to the start of the
call. The access code is 46756966. The conference call will also be webcast
live over the Internet. The webcast can be accessed by logging on to the
"Investor Relations" section of the Luna Innovations website,
http://www.lunainnovations.com , prior to the event. The webcast will be
archived under the "Webcasts and Presentations" section of the Luna
Innovations website for at least 30 days following the conference call.

####

About Luna Innovations
Luna Innovations Incorporated researches, develops and commercializes innovative technologies in molecular technology and sensing solutions. Luna Innovations accelerates the process of bringing new and innovative products to market by focusing on technologies that can fulfill identified market needs and then takes these technologies from the applied research stage through commercialization. Since its inception, Luna Innovations has successfully developed products for the energy, telecommunications, life sciences and defense industries. Headquartered in Roanoke, Virginia, the company has research, development and manufacturing facilities in Blacksburg, Charlottesville, Hampton, and Danville, Virginia, and a sales office in McLean, Virginia. Additional information can be found at http://www.lunainnovations.com . ( Logo: http://www.newscom.com/cgi-bin/prnh/20060627/LUNALOGO ) Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995 This press release includes information that constitutes "forward-looking statements" made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995, including but not limited to (i) the acquisition of the swept tunable laser technology will allow the company to compete more effectively in its existing fiber optic test and measurement markets and open up new markets in industrial and medical sensing, (ii) the company will aggressively pursue opportunities for its newly acquired tunable laser technology in industrial and medical sensing markets, (iii) the FDA- accredited third party review may shorten the overall time required to receive FDA clearance for the company's EDAC product, (iv) the company's new distributed sensing technique is expected to significantly reduce the expense associated with the deployment and maintenance of fiber optics, (v) the company anticipates continued strong growth in both its product and technology development divisions in 2007, and (vi) statements regarding revenue and net loss guidance for fiscal year 2007. The company attempts, whenever possible, to identify forward-looking statements by words such as "intends," "will," "plans," "anticipates," "expects," "may," "estimates," "believes," "should," "projects," or "continue," or the negative of those words and other comparable words. Similarly, statements that describe the company's business strategy, goals, prospects, opportunities, outlook, objectives, plans or intentions are also forward-looking statements. Luna Innovations wishes to take advantage of the "safe harbor" provided by the Private Securities Litigation Reform Act of 1995 and you are cautioned that actual events or results may differ materially from the expectations expressed in such forward-looking statements as a result of various factors, including risks and uncertainties, many of which are beyond the company's control. Factors that could cause actual results to differ materially from the expectations expressed in such forward-looking statements include, but are not limited to: the company's ability to manage its growth effectively; the company's ability to successfully identify market needs for new products; the company's continued reliance on contract research, including government grants and contracts available only to small businesses, for a significant portion of its revenue; the risk that the company may become ineligible for small business government grants and contracts in the future; the effect of competition in its markets and changes in customer demand; the risk that company's proprietary rights may be insufficient to protect its technologies, including potential claims by third parties that the company infringes their intellectual property rights; the potential impact of federal audits and investigations; delay in obtaining clearance by the U.S. Food and Drug Administration or other regulatory requirements; continued difficulty in, or increased costs related to, hiring, training and retaining skilled employees; unanticipated manufacturing or supply problems; a slowdown in the overall economy; and uncertainty in the global political environment. Additional factors that may affect the future results of the company are set forth in its Registration Statement on Form S-1, its quarterly and annual reports on Form 10-Q and Form 10-K, respectively, and other filings with the Securities and Exchange Commission ("SEC"), which are available at the SEC's website at http://www.sec.gov , and at Luna Innovations' website at http://www.lunainnovations.com . These risk factors are updated from time to time through the filing of periodic reports and registration statements with the SEC. The statements made in this press release are based on information available to the company as of the date of this release and Luna Innovations undertakes no obligation to update any of the forward-looking statements herein after the date of this press release.

Luna Innovations Incorporated
                         Consolidated Balance Sheets

                                                 December 31,    December 31,
                                                     2006            2005
                                                --------------  --------------
    Assets                                        (unaudited)
    Current assets
      Cash and cash equivalents                  $ 17,866,753    $ 12,514,839
      Accounts receivable, net                      7,233,406       5,129,911
      Refundable income taxes                         396,062         514,797
      Inventory                                       843,294         448,475
      Other current assets                            503,703         227,409
                                                --------------  --------------
        Total current assets                       26,843,218      18,835,431
    Property and equipment, net                     5,730,094       2,972,287
    Intangible assets, net                          2,031,489         999,544
    Deferred offering costs                               -           710,018
    Deferred tax asset                                600,000         600,000
    Other assets                                       12,413          16,550
                                                --------------  --------------
           Total assets                          $ 35,217,214    $ 24,133,830
                                                ==============  ==============
    Liabilities and stockholders' equity
    Current liabilities
      Current portion of capital lease
       obligation                                $     88,576    $     98,820
      Current portion of long-term debt
       obligation                                     214,955               -
      Accounts payable                              2,757,381       3,647,505
      Accrued liabilities                           3,623,395       1,788,162
      Deferred credits                                874,676       1,458,393
                                                --------------  --------------
        Total current liabilities                   7,558,983       6,992,880
    Long-term capital lease obligation                 28,557         117,134
    Long-term debt obligation                       5,000,000       5,214,955
    Deferred credits and other long term
     liabilities                                      554,418         450,000
                                                --------------  --------------
        Total liabilities                          13,141,958      12,774,969
                                                --------------  --------------
    Redeemable Class B common stock, 308,216
     shares at December 31, 2005                            -         504,984
                                                --------------  --------------
    Stockholders' equity:
      Preferred stock, par value $0.001,
       5,000,000 shares authorized at December
       31, 2006, no shares issued and
       outstanding at December 31, 2006                     -               -
      Common stock
        Common stock, par value $0.001,
         100,000,000 and 23,257,094 shares
         authorized at December 31, 2006 and
         December 31, 2005, respectively,
         9,911,546 shares issued and outstanding
         at December 31, 2006                           9,912               -
        Class A voting common stock, par value
         $0.001, 7,164,463 shares authorized at
         December 31, 2005, 2,834,814 shares
         issued and outstanding at December 31,
         2005                                               -           2,835
        Class B non-voting common stock, par
         value $0.001, 13,707,297 shares
         authorized at December 31, 2005,
         734,427 shares issued and outstanding
         at December 31, 2005                               -             734
        Class C voting common stock, par value
         $0.001, 5,656,472 shares authorized at
         December 31, 2005, 2,131,474 shares
         issued and outstanding at December 31,
         2005                                               -           2,131
      Additional paid-in capital                   31,585,762      10,935,049
      Accumulated deficit                          (9,520,418)        (86,872)
                                                --------------  --------------
        Total stockholders' equity                 22,075,256      10,853,877
                                                --------------  --------------
           Total liabilities and stockholders'
            equity                               $ 35,217,214    $ 24,133,830
                                                ==============  ==============



                        Luna Innovations Incorporated
                    Consolidated Statements of Operations

                              Three Months Ended       Twelve Months Ended
                                 December 31,              December 31,
                           ------------ ------------ ------------ ------------
                              2006         2005         2006         2005
                           ------------ ------------ ------------ ------------
                                  (unaudited)        (unaudited)
    Revenues:
       Contract research
        revenues           $ 5,810,797  $ 4,267,946  $18,787,863  $15,379,667
       Product and license
        revenues             2,236,376    1,074,221    4,757,779    1,074,221
                           ------------ ------------ ------------ ------------
          Total revenues     8,047,173    5,342,167   23,545,642   16,453,888
    Cost of revenues:
       Contract research
        costs                4,631,659    4,012,555   14,232,063   12,552,122
       Product and license
        costs                  983,166      409,772    2,178,135      409,772
                           ------------ ------------ ------------ ------------
          Total cost of
           revenues          5,614,825    4,422,327   16,410,198   12,961,894
                           ------------ ------------ ------------ ------------
    Gross Profit             2,432,348      919,840    7,135,444    3,491,994
    Operating expense        5,303,766    3,050,978   17,109,043    6,003,644
                           ------------ ------------ ------------ ------------
    Operating loss          (2,871,418)  (2,131,138)  (9,973,599)  (2,511,650)
                           ------------ ------------ ------------ ------------
    Other income (expense)
       Other income
        (expense)               22,548        1,684       32,879        1,592
       Interest income /
        (expense), net         170,024       33,955      515,818      (41,251)
                           ------------ ------------ ------------ ------------
    Total other income
     (expense)                 192,572       35,639      548,697      (39,659)
                           ------------ ------------ ------------ ------------
    Loss before income
     taxes                  (2,678,846)  (2,095,499)  (9,424,902)  (2,551,309)
    Income tax expense
     (benefit)                     -       (369,979)      12,829     (557,252)
                           ------------ ------------ ------------ ------------
    Net loss               $(2,678,846) $(1,725,520) $(9,437,731) $(1,994,057)
                           ============ ============ ============ ============
    Net loss per share:
       Basic               $     (0.27) $     (0.33) $     (1.14) $     (0.53)
                           ============ ============ ============ ============
       Diluted             $     (0.27) $     (0.33) $     (1.14) $     (0.53)
                           ============ ============ ============ ============
    Weighted average
     shares:
       Basic                 9,883,057    5,254,336    8,283,074    3,735,811
                           ============ ============ ============ ============
       Diluted               9,883,057    5,254,336    8,283,074    3,735,811
                           ============ ============ ============ ============



                        Luna Innovations Incorporated
                    Consolidated Statements of Cash Flows

                                                       Twelve Months Ended
                                                           December 31,
                                                  ----------------------------
                                                       2006           2005
                                                  -------------  -------------
                                                    (unaudited)
    Cash flows used in operating activities
      Net loss                                    $ (9,437,731)  $ (1,994,057)
      Adjustments to reconcile net loss to net
       cash provided by operating activities:
        Depreciation and amortization                1,134,777        540,145
        Deferred income taxes                              -         (157,251)
        Share-based compensation                     1,762,899        168,926
      Change in assets and liabilities:
        Accounts receivable                         (2,103,495)    (1,314,485)
        Refundable income taxes                        118,735        362,005
        Other assets                                  (654,560)       (26,194)
        Accounts payable and accrued expenses          723,445      1,911,095
        Deferred revenues                             (679,299)       422,227
                                                  -------------  -------------
          Net cash used in operating activities     (9,135,229)       (87,589)
                                                  -------------  -------------
    Cash flows used in investing activities
      Acquisition of property and equipment         (2,828,046)      (877,144)
      Intangible property costs                       (558,909)      (430,847)
      Net cash from acquisition of Luna
       Technologies                                        -           33,676
      Capitalized software development costs               -         (122,642)
                                                  -------------  -------------
          Net cash used in investing activities     (3,386,955)    (1,396,957)
                                                  -------------  -------------
    Cash flows from financing activities
      Net payments on line of credit                       -       (1,500,000)
      Payments on capital lease obligations            (98,819)      (107,177)
      Proceeds from convertible debt                                5,000,000
      Proceeds from the issuance of common stock,
       net                                          17,881,900      9,912,468
      Proceeds from the exercise of options and
       warrants                                         91,017         84,458
                                                  -------------  -------------
          Net cash from financing activities        17,874,098     13,389,749
                                                  -------------  -------------
    Net change in cash                               5,351,914     11,905,203
    Cash - beginning of period                      12,514,839        609,636
                                                  -------------  -------------
    Cash - end of period                          $ 17,866,753   $ 12,514,839
                                                  =============  =============
    Supplemental disclosure of cash flow
     information
    Cash paid for interest                        $     45,341   $    108,211
    Cash paid for income taxes                    $     12,829   $        -
    Property and equipment financed by capital
     leases                                       $        -     $     11,700

For more information, please click here

Contacts:
Contact Luna by phone at 1.540.769.8400
by mail at 1703 South Jefferson Street SW Suite 400, Roanoke, VA 24016
or by
e-mail at

Copyright © PR Newswire Association LLC.

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

Sensors

Compact Vibration Harvester Power Supply with Highest Efficiency Opens Door to “Fix-and-Forget” Sensor Nodes July 23rd, 2014

Nano-sized Chip "Sniffs Out" Explosives Far Better than Trained Dogs: TAU researcher's groundbreaking sensor detects miniscule concentrations of hazardous materials in the air July 23rd, 2014

Tiny laser sensor heightens bomb detection sensitivity July 19th, 2014

Iranian Scientists Use Nanosensors to Achieve Best Limit for Early Cancer Diagnosis July 19th, 2014

Materials/Metamaterials

Silicene Labs Announces the Launch of Patent-Pending, 2D Materials Composite Index™ : The Initial 2D Materials Composite Index™ for Q2 2014 Is: 857.3; Founders Include World-Renowned Physicist and Seasoned Business and IP Professionals July 24th, 2014

Iranian Scientists Produce Transparent Nanocomposite Coatings with Longer Lifetime July 24th, 2014

Penn Study: Understanding Graphene’s Electrical Properties on an Atomic Level July 22nd, 2014

NUS scientists use low cost technique to improve properties and functions of nanomaterials: By 'drawing' micropatterns on nanomaterials using a focused laser beam, scientists could modify properties of nanomaterials for effective applications in photonic and optoelectric applicat July 22nd, 2014

Announcements

Silicene Labs Announces the Launch of Patent-Pending, 2D Materials Composite Index™ : The Initial 2D Materials Composite Index™ for Q2 2014 Is: 857.3; Founders Include World-Renowned Physicist and Seasoned Business and IP Professionals July 24th, 2014

Iranian Scientists Produce Transparent Nanocomposite Coatings with Longer Lifetime July 24th, 2014

Deadline Announced for Registration in 7th Int'l Nanotechnology Festival in Iran July 23rd, 2014

A Crystal Wedding in the Nanocosmos July 23rd, 2014

Financial Reports

Harris & Harris Group to Host Conference Call on Second-Quarter 2014 Financial Results on August 15, 2014 July 23rd, 2014

Aspen Aerogels, Inc. Schedules Second Quarter 2014 Earnings Release and Conference Call July 15th, 2014

Nanometrics to Announce Second Quarter Financial Results on July 30, 2014 July 9th, 2014

Small, but heading for the big time: Nanobiotix revenue for the 1st quarter of 2014 and new composition of the shareholding May 12th, 2014

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More














ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







© Copyright 1999-2014 7th Wave, Inc. All Rights Reserved PRIVACY POLICY :: CONTACT US :: STATS :: SITE MAP :: ADVERTISE